Stereotactic radiosurgery (SRS) and stereotactic radiation therapy (SRT) techniques are used to deliver high doses per fraction to various types of intra-cranial targets. LINAC-based solutions are growing in prevalence due to recent advances in technologies such as high-definition multi-leaf collimators and volumetric arc therapy radiation delivery. A wide variety of clinical pathologies including intracranial metastases, meningioma, glioblastoma, arteriovenous malformation, acoustic neuroma, and trigeminal neuralgia have been successfully treated using SRS/SRT techniques. These lesions can be in virtually at any location within the cranium. Several publications have shown a wide dispersion of intermediate dose conformality (intermediate dose spill) indices such as the Paddick Gradient Index or R50% for lesions of a specific volume. A complete explanation of this dispersion is lacking but location has been suggested as a contributing factor. While prior studies of PTV location in SRS/SRT are retrospective in nature, we have conducted a prospective study to ascertain the potential effects of location within the cranium on plan intermediate dose conformality as measured by R50% while controlling for lesion volume, lesion shape, prescription (Rx) dose, and Rx isodose surface. Lesion volumes utilized in this study are consistent with metastatic disease presentation. Results indicate only a weak relationship between intermediate dose conformality as measured by R50% and the lesion location when considering nine different, strategically placed lesions. Close proximity to critical structures can reduce the degree of conformality, but the effect appears to be minimal. Single isocenter multiple target cases were studied in addition to single target plans. All critical structure doses observed in this study were found to be within the recommendations of AAPM Task Group report 101. Lesion location does not appear to be a significant contributing factor to the observed variation of dose conformality seen in several SRS/SRT publications.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.meddos.2021.09.006DOI Listing

Publication Analysis

Top Keywords

intermediate dose
16
dose conformality
16
location cranium
8
contributing factor
8
conformality measured
8
measured r50%
8
lesion location
8
location
7
dose
6
conformality
5

Similar Publications

Purpose: Local recurrence of prostate cancer (PCa) after radiation therapy (RT) typically occurs at the site of dominant tumor burden, and recent evidence confirms that magnetic resonance imaging (MRI) guided tumor dose escalation improves outcomes. With the emergence of prostate-specific membrane antigen (PSMA) positron emission tomography (PET), we hypothesize that PSMA-PET and MRI may not equally depict the region most at risk of recurrence after RT.

Methods And Materials: Patients with intermediate- to high-risk PCa and MRI plus PSMA-PET performed before RT were identified.

View Article and Find Full Text PDF

Evaluation of radiation therapy on grafted and non-grafted defects: an experimental rat model.

J Appl Oral Sci

January 2025

Universidade Federal de Uberlândia, Faculdade de Odontologia, Departamento de Periodontia e Implantodontia, Uberlândia, Brasil.

Objective: This study aimed to assess the effects of a single-dose radiation therapy (15 Gy) on grafted and non-grafted defects, bone microarchitecture, and collagen maturity.

Methodology: Bone defects were surgically created in rat femurs. The right femur defect was filled with blood clot (group "Clot") and the left femur defect by deproteinized bovine bone mineral graft (group "Xenograft").

View Article and Find Full Text PDF

This retrospective study aimed to compare the clinical outcomes of intensity-modulated radiation therapy (IMRT) and proton beam therapy (PBT). A total of 606 patients diagnosed with prostate cancer between January 2008 and December 2018 were included. Of these patients, 510 received PBT up to a dose of 70-78 Gy (relative biological effectiveness) and 96 patients received IMRT up to a dose of 70-78 Gy.

View Article and Find Full Text PDF

Intermediate-dose immune tolerance induction outperforms with faster success, less bleeding, and no added cost in comparison with low dose: a multicenter randomized clinical trial.

Res Pract Thromb Haemost

January 2025

Hemophilia Comprehensive Care Center, Hematology Center, Beijing Key Laboratory of Pediatric Hematology-Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.

Background: Low-dose (LD) or intermediate-dose (MD) immune tolerance induction (ITI) is effective in children with severe hemophilia A (SHA) with high-titer inhibitors (HTIs) and is attractive in countries with economic constraints. However, high-quality evidence of their use is lacking.

Objectives: This was a multicenter randomized clinical trial comparing the efficacy, safety, and medication cost between LD-ITI and MD-ITI for SHA-HTI children.

View Article and Find Full Text PDF

Purpose: This study aimed to evaluate the prognostic significance of magnetic resonance imaging (MRI) parameters on biochemical failure-free survival (BFS) in patients diagnosed with intermediate-risk prostate cancer and treated with robotic ultrahypofractionated stereotactic body radiotherapy (SBRT) without androgen deprivation therapy (ADT).

Methods: A retrospective analysis was conducted in patients with intermediate-risk prostate cancer undergoing robotic SBRT delivered in five fractions with a total radiation dose of 35-36.25 Gy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!